Richard Miller
Co-founder and CEO of Corvus Pharmaceuticals, leading the company through clinical development of the ITK inhibitor soquelitinib with experience in translational medicine and clinical trials.
Best podcasts with Richard Miller
Ranked by the Snipd community
Jan 28, 2026 • 27min
Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
Richard Miller, Co-founder and CEO of Corvus Pharmaceuticals, leads clinical development of the ITK inhibitor soquelitinib. He discusses data consistency and a novel mechanism. He talks about durability and possible immune reset. He outlines intermittent and once-daily dosing plans, timing for 90‑day results, biomarkers, trial diversity, and plans to expand ITK into oncology and rare diseases.
